nemolizumab   Click here for help

GtoPdb Ligand ID: 8720

Synonyms: CD14152 | CIM 331 | CIM331
Immunopharmacology Ligand
Compound class: Antibody
Comment: Nemolizumab is an investigational monoclonal targeting the α subunit of the IL-31 receptor. Nemolizumab has been designed for treating or preventing inflammatory diseases [3].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis of patented peptide sequences reveals that the heavy and light variable domains of nemolizumab are identical to SEQ ID NO: 210 and SEQ ID NO: 220 respectively, in patent US8575317 B2 [4]. This combination of peptides corresponds to one of the preferred antibodies, designated as H44L17 therein.
Click here for help
1. Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, Etoh T, Mihara R, Nakano M, Ruzicka T. (2018)
Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
J Allergy Clin Immunol, 142 (4): 1121-1130.e7. [PMID:29753033]
2. Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. (2020)
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
N Engl J Med, 383 (2): 141-150. [PMID:32640132]
3. Kasutani K, Fujii E, Ohyama S, Adachi H, Hasegawa M, Kitamura H, Yamashita N. (2014)
Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice.
Br J Pharmacol, 171 (22): 5049-58. [PMID:24946165]
4. Kuramochi T, Kasutani K, Ohyama S, Tsunoda H, Igawa T, Tachibana T, Shiraiwa H, Esaki K. (2013)
Anti-NR10 antibody and use thereof.
Patent number: US8575317 B2. Assignee: Chugai Seiyaku Kabushiki Kaisha. Priority date: 05/12/2007. Publication date: 05/11/2013.
5. Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, Imayama S, Kato M, Hasebe I, Taira K et al.. (2016)
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
Br J Dermatol, 174 (2): 296-304. [PMID:26409172]